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We present a dialysis technique to direct the self-assembly of paclitaxel (PTX)-loaded nanoparticles (NPs) using
methoxypolyethylene glycol-poly(D,L-lactide) (MPEG-PLA) and PLA, respectively. The composition, morphology,
particle size and zeta potential, drug loading content, and drug encapsulation efficiency of both PTX-PLA NPs and
PTX-MPEG-PLA NPs were characterized by X-ray diffraction, Fourier transform infrared spectroscopy, transmission
electron microscopy, dynamic light scattering, electrophoretic light scattering, and high-performance liquid
chromatography. The passive targeting effect and in vitro cell viability of the PTX-MPEG-PLA NPs on HeLa cells were
demonstrated by comparative cellular uptake and MTT assay of the PTX-PLA NPs. The results showed that the
PTX-MPEG-PLA NPs and PTX-PLA NPs presented a hydrodynamic particle size of 179.5 and 441.9 nm, with a
polydispersity index of 0.172 and 0.189, a zeta potential of −24.3 and −42.0 mV, drug encapsulation efficiency of
18.3% and 20.0%, and drug-loaded content of 1.83% and 2.00%, respectively. The PTX-MPEG-PLA NPs presented
faster release rate with minor initial burst compared to the PTX-PLA NPs. The PTX-MPEG-PLA NPs presented superior
cell cytotoxicity and excellent cellular uptake compared to the PTX-PLA NPs. These results suggested that the
PTX-MPEG-PLA NPs presented more desirable characteristics for sustained drug delivery compared to PTX-PLA NPs.
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A nano drug delivery system can transport anticancer
agents and preferentially reach tumor sites, owing to the
advantages of reduced clearance from the reticuloendothe-
lial system (RES), increased tumor accumulation through
enhanced permeation and retention (EPR), and effective
cellular uptake, as they offer a less invasive alternative
compared with conventional therapeutic cocktails (e.g.,
chemotherapy, radiation therapy, and surgery), thereby
minimizing the excessive toxic side effects and maximizing
the efficacy of drugs in clinical trials [1,2]. Some character-
istics can be the prerequisites for a nano drug delivery* Correspondence: houzhenqing@xmu.edu.cn; xly885@163.com
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in any medium, provided the original work is psystem: (1) a low cytotoxicity and the possibility of bio-
degradability of the vector itself, (2) versatile surface func-
tionalization, (3) a high drug-loaded content related with
elevated therapeutic efficacy, (4) a good dispersibility and
colloidal stability of the vector in physiological conditions,
(5) a low level of protein adsorption related with a pro-
longed circulation time, (6) a low degree of premature
leakage and the possibility for controlled release of drugs,
and (7) can be targeted to cell/tissue of choice and effec-
tive cellular uptake [3-5].
Self-assembled nanoparticles (NPs) have attracted con-
siderable interest for their potential use in drug delivery
and cancer therapy since they can encapsulate a series of
poorly water-soluble anticancer drugs and release them
in a sustained manner at their target site [6-8]. Self-
assembly technique can provide a simple and low-cost
method for producing NPs in a controllable way [9].
Polymeric amphiphiles consisting of hydrophilic and
hydrophobic parts can form nanosized self-assembliespen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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hydrophilic shell contributes to their prolonged circula-
tion to increase their ability of reaching the target tumor
tissue after systemic administration in vivo. More im-
portantly, because of their abnormally leaky vasculature
and lack of an effective lymphatic drainage system, self-
assembled NPs also tend to be accumulated in tumor
sites [10].
Paclitaxel (PTX), one of the most exciting anticancer
agents, was currently available. It showed effective activ-
ity by inhibiting various tumors and had been used clin-
ically in the treatment of metastatic breast cancer,
ovarian cancer, and several other malignancies [11]. New
research has shown that PTX has antiangiogenic activity
by inhibiting vascular endothelial cell proliferation, mo-
tility, and cord/tube formation at extremely low concen-
trations [12]. For these reasons, we chose PTX as the
model chemotherapeutic agent. Despite its potent anti-
cancer activity, unfortunately limited by poor water solu-
bility and toxic side effects, it has no great advantage in
tumor targeting for drug delivery and cancer therapy [13].
A series of efforts has been directed to the development
of alternative delivery systems for PTX. Poly(D,L-lactide)
(PLA), a FDA-approved biodegradable and non-cytotoxic
material with a good track record in offering great poten-
tial for controlled release, has stood out and been exten-
sively used in the formulation of NPs for biotechnology
and drug delivery applications [14]. However, in aqueous
solution, the drug-loaded PLA NPs presented poor dis-
persibility and colloidal stability; in addition, the PLA NPs
were not amenable to rapid clearance from the circulation
by the RES, immediately after their injection into the
systemic circulation. A safe and effective way to answer
this problem is to design long-circulating NPs with hydro-
philic polymers. Polyethylene glycol (PEG), also a FDA-
approved polymer highly soluble in water, has been widely
used as a long-circulating agent to improve the biocom-
patibility and increase the colloidal stability of NPs
through steric hindrance, which was often incorporated in
drug carriers for delivery to the human body, according to
its resistance against opsonization, the process through
which protein adsorption is enhanced to induce phagocy-
tosis [15-17]. Thereby, methoxypolyethylene glycol-poly
(D,L-lactide) (MPEG-PLA) diblock copolymers have been
of great interest as a completely biocompatible material
for drug delivery [18,19]. Moreover, MPEG-PLA could
make long circulation possible for pharmaceutical uses
and opened new perspectives for controlled drug delivery
in particular.
In this paper, we present a dialysis technique to direct
the self-assembly of PTX-loaded NPs using MPEG-PLA
diblock copolymers and PLA, respectively. The hydro-
phobic polymeric core of the platform readily encapsu-
lated the water-insoluble drug for systemic delivery. Thephysicochemical properties of the PTX-MPEG-PLA NPs
were characterized by Fourier transform infrared spec-
troscopy (FTIR), X-ray diffraction (XRD), dynamic light
scattering (DLS), static light scattering (SLS), transmis-
sion electron microscopy (TEM), and confocal laser
scanning microscopy (CLSM). In vitro drug release pro-
files and cytotoxicity tests were also conducted. The
PTX-PLA NPs were also prepared and characterized in
the same way and used for comparison.
Methods
Materials
PTX (purity grade > 90%) was purchased from Qilu Phar-
maceutical Co., Ltd. (Shandong, China). PLA (50 kDa)
and MPEG-PLA (10%) were provided by Daigang BIO
Engineer Co., Ltd. (Shandong, China). A dialysis bag (Mw
cutoff = 8,000 to 14,000 Da) was ordered from Greenbird
Inc. (Shanghai, China). Double-distilled water was used
throughout. All chemical reagents were of analytical grade
and used without further purification unless otherwise
stated. All solutions used in a high-performance liquid
crystal (HPLC, Waters Associates, Milford, MA, USA)
analysis were filtered and degassed using a 0.22-μm mem-
brane filter with a filtration system.
Preparation of the PTX-MPEG-PLA NPs
The PTX-MPEG-PLA NPs were prepared by a facile dia-
lysis method. In brief, 100 mg of MPEG-PLA and 10 mg
of PTX were codissolved in 10 mL of organic solvent
(acetone, unless specified) accompanied by vigorous stir-
ring; then the resulting organic phase was introduced
into a dialysis bag. Subsequently, the dialysis bag was
placed with gentle agitation (100 rpm) into 1,000 mL of
water as the aqueous phase. The organic phase was dia-
lyzed against the aqueous phase for 6 h. Following this,
the aqueous phase was subjected to repeated cycles of
replacing with fresh water at designed time points (1, 2,
3, 4, 5, and 6 h) to remove the diffused organic phase by
dialysis. The as-prepared PTX-MPEG-PLA NPs were ly-
ophilized for 24 h using a freeze drier (Labconco Plus
12, Labconco, Kansas City, MO, USA) and stored at 4°C
for future use. The PTX-PLA NPs were prepared in a
similar way by using 100 mg of PLA. The drug loading
content and drug encapsulation efficiency of PTX-
MPEG-PLA NPs and PTX-PLA NPs were determined
by a HPLC system consisting of a Waters 2695 Sepa-
ration Module and a Waters 2996 Photodiode Array
Detector with the following conditions: stationary phase:
Thermo C18 column (150 mm × 4 mm, 5 μm), tem-
perature 26 ± 1°C; mobile phase: methanol/ultrapure
water (65/35, v/v), freshly prepared, filtered through a
0.22-μm Millipore (Billerica, MA, USA)membrane filter
before use, and degassed utilizing a sonication method;
elution flow rate, 0.8 mL/min; and detection wavelength,
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based on the peak area at the retention time of 7.5 min
by reference to a calibration curve.
XRD analysis
The physical state of PTX in the MPEG-PLA NPs or
PLA NPs was analyzed using a Philips X’Pert Pro Super
X-ray diffractometer (Philips, Amsterdam, Netherlands)
equipped with CuKα radiation generated at 30 mA and
40 kV. The diffraction angle was increased from 5° to
60°, with a step size of 0.05. As control, the characteris-
tic of PTX and MPEG-PLA NPs/PLA NPs, and the
physical mixture of PTX and MPEG-PLA NPs/PLA NPs
with the same ratio were investigated as well.
FTIR analysis
FTIR spectra were obtained using a NicoletAVTAR36
FTIR spectrometer (Thermo Scientific, Logan, UT, USA)
with a resolution of 4 cm−1 from 4,000 to 400 cm−1. The
PTX-MPEG-PLA NPs or PTX-PLA NPs were lyophi-
lized to obtain the FTIR sample. Two milligrams of
dried powder was added to 200 mg of KBr. The powder
was pressed into a pellet for analysis. Besides, the FTIR
spectra of MPEG-PLA NPs/PLA NPs and pure drug
were obtained as control.
Particle size, polydispersity index, surface charge,
and morphology
Average particle size and polydispersity index (PDI) were
determined by DLS using a Malvern Zetasizer Nano-ZS
(Malvern Instruments, Worcestershire, UK). Zeta poten-
tial was evaluated by electrophoretic light scattering
(ELS) with Zetaplus (Brookhaven Instruments Corpo-
ration, Holtsville, NY, USA). Particle size was evaluated
by intensity distribution, and particle size distribution
was represented by PDI. The morphology of the PTX-
MPEG-PLA NPs was observed on a JEM 2100 transmis-
sion electron microscope (JEOL, Tokyo, Japan) operating
at 200 kV. One drop of the suspension was diluted with
water, subsequently placed on a carbon-coated copper
grid, and lastly, dried in the air before observation. PTX-
PLA NPs were used for comparison.
In vitro drug release behavior
Evaluation of in vitro release behavior was conducted to
examine how rapidly PTX was released from the PTX-
MPEG NPs. The output obtained by the dynamic dialy-
sis method provided a correlation with in vivo drug
release. The lyophilized NPs (equivalent to 5 mg of
PTX) were dispersed in 2 mL of PBS (1/15 M, pH 7.4),
and the dispersion was added into a dialysis bag. The re-
lease experiment was initiated by placing the end-sealed
dialysis bag in 48 mL of PBS (1/15 M, pH 7.4). The sys-
tem was kept on a magnetic stirrer under controlledconditions (100 rpm, 37°C). At predetermined time in-
tervals, 2 mL of the release medium was completely
withdrawn and subsequently replaced with the same vol-
ume of fresh PBS solution. The concentration of PTX in
the samples was measured by HPLC. The lyophilized
PTX-PLA NPs (equivalent to 5 mg of PTX) were used
for comparison.
In vitro cellular uptake
In vitro cellular uptake was employed to investigate the
distribution of PTX-loaded MPEG-PLA NPs in the cell.
Following a 24-h culture of HeLa cells in a six-well plate,
100 μL of rhodamine B-labeled PTX-MPEG-PLA NPs
(1 mg/mL) was added to the medium and incubated fur-
ther for 48 h. The HeLa cells were washed five times with
PBS and continuously stained with 50 μL of Hochest 33258
(0.005 mg/mL). The cells were observed with CLSM (Leica
TCS SP5, Leica Microsystems, Mannheim, Germany). Cells
treated with rhodamine B-labeled PTX-PLA NPs were used
for comparison.
In vitro cell viability assays
A549 cells were cultured in standard cell media
recommended by the American Type Culture Collec-
tion. Cells seeded in 96-well plates were incubated with
a series of increasing concentrations of PTX-MPEG-PLA
NPs for 48 h. Subsequently, relative cell viability was
assessed by the standard MTT assay. Cells treated with
free PTX and cells treated with the PTX-PLA NPs were
compared.
Results and discussion
Preparation of the PTX-MPEG-PLA NPs
Acetone is water-miscible and a good solvent for
MPEG-PLA. PTX and MPEG-PLA were first codissolved
in this organic phase and was then extensively dialyzed
against the aqueous phase. In the dialysis process, ace-
tone was gradually removed and slowly replaced with
water, which resulted in the hydrophobic PLA compris-
ing a core while the hydrophilic PEG extended to the
outer aqueous environment to form a shell. Thus, a min-
imal energy state was attained in aqueous media, and
the lipophilic drug PTX spontaneously transferred inside
the hydrophobic cores of particles because of the driving
force of hydrophobic interaction (Figure 1). Further-
more, inter- and/or intramolecular hydrogen bonds be-
tween hydroxyl groups of PEG will stabilize the NPs.
Thus, the amphiphilic MPEG-PLA can form NPs load-
ing PTX drug with a well-defined core-shell structure by
self-assembly in aqueous media, and the structure is be-
lieved to possess a self-stabilization function. The deter-
mined drug entrapment efficiency and drug-loaded content
of PTX-MPEG-PLA NPs by HPLC were 18.3 ± 0.4% and
Figure 1 Schematic representations of PTX-PLA NPs and
PTX-MPEG-PLA NPs.
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and 2.00 ± 0.07%.XRD and FTIR analysis
XRD diffraction patterns of PTX, both blank MPEG-PLA
NPs and PLA NPs, physical mixture, and drug-loadedFigure 2 FTIR and XRD analysis of the PTX, physical mixture, and dru
(c), MPEG-PLA NPs (d), and PTX-MPEG-PLA NPs (e). (B) XRD patterns of PTX
(d), MPEG-PLA NPs (e), physical mixture of PTX and MPEG-PLA NPs (f), andNPs are presented in Figure 2B. It was clear that pure
PTX showed partially sharp crystalline peaks, representa-
tive of the characteristics of a molecular compound with
some crystallinity, whereas a broad peak was presented in
blank NPs, indicating that blank NPs were amorphous
and lack crystalline peaks. Some crystalline drug signals
were still detectable in the physical mixture. A decrease in
the intensity of the peaks was explained by a lower loading
of the drug per unit weight of the physical mixture com-
pared to pure PTX. Conversely, the crystalline peaks al-
most disappeared in the drug-loaded NPs whereas the
amorphous characteristics resembled those of blank NPs,
indicating that the drug was encapsulated within the NPs
and suggesting that PTX in the NP matrix was molecu-
larly dispersed or in the amorphous form.
The physicochemical state of incorporating drug in the
NPs is one important factor that affects the drug release
behavior. As shown in Figure 2B, there was no change in
the absorption peaks between the blank NPs and drug-
loaded NPs. Of note, the absorption peaks of the pure
drug were almost shielded because of drug entrapment
effect. Based on the spectral characteristics of PTX, blank
NPs and drug-loaded NPs, it should be inferred synthetic-
ally that there was no chemical interactions between PTX
and blank NPs because of no appearances of new func-
tional groups. Therefore, the individual physicochemical
characteristics will not change in vitro and in vivo.Particle size, PDI, surface charge, and morphology
DLS and ELS (see Figure 3) showed that the PTX-
MPEG-PLA NPs and PTX-PLA NPs presented a hydro-
dynamic particle size of 179.5 and 441.9 nm, with a
PDI of 0.172 and 0.189, and a zeta potential of −24.3g-loaded NPs. (A) FTIR spectra of PTX (a), PLA NPs (b), PTX-PLA NPs
(a), PLA NPs (b), physical mixture of PTX and PLA NPs (c), PTX-PLA NPs
PTX-MPEG-PLA NPs (g).
Figure 3 Particle size and zeta potential. Particle size determined by DLS (A) and zeta potential determined by ELS (B) of PTX-MPEG-PLA NPs
and PTX-PLA NPs.
Cui et al. Nanoscale Research Letters 2013, 8:301 Page 5 of 8
http://www.nanoscalereslett.com/content/8/1/301and −42.0 mV, respectively. Smaller particle size favored
EPR targeting; lower PDI indicated good dispersibility, a
prerequisite of good stability. Higher zeta potential sup-
ported that the NPs did not aggregate much in aqueous
state in general and in physiologically relevant media
in particular. Knowledge on these characteristics of a NP
system can help predict the fate and biodistribution of NPs
at the cellular or animal level in vivo after administration
[1,6]. As clearly seen from Figure 3A, the hydrodynamic
particle size of PTX-MPEG-PLA NPs was much less thanFigure 4 TEM images of PTX-PLA NPs (A, B) and PTX-MPEG-PLA NPs (that of PTX-PLA NPs; the particle size is compatible in
EPR targeting attributed to the leaky nature of tumor ves-
sels. Therefore, PTX-MPEG-PLA NPs were chosen as an
effective model drug carrier as their particle size distribu-
tion and zeta potential distribution were narrow.
Additionally, TEM images revealed that PTX-MPEG-
PLA NPs were regularly spherical in shape and have a
generally smooth surface with an approximate average
size of around 100 nm, and the core particles contain
a lighter outer region (see Figure 4). The average sizeC, D).
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well consistent with the size determined by TEM. These
factors were possibly responsible for the following dif-
ferences. First, in the case of the TEM method, TEM
depicted the size in the dried state of the sample, whereas
DLS determined the size in the hydrated state of the sam-
ple. Second, the polymer shell of the particle surface
tended to expand in aqueous environment which inevit-
ably increased the hydrodynamic size of NPs because of
solvent effect. Third, some NPs may be likely aggregated
in the aqueous environment.
Dialysis offered an easy and effective method for the
preparation of small and well-distributed NPs. At present,
the mechanism of NP formation by dialysis method is not
fully understood. It was thought that it may be based on a
mechanism similar to that of nanoprecipitation. It was
based on the utilization of a physical barrier that allowed
the passive transport of organic solvents to slow down the
mixing of MPEG-PLA with water; the organic solvent
played a role in the morphology and particle size distribu-
tion of the NPs [20]. The presence of hydrophilic PEG
chain, small particle size, high zeta potential, sharp curve
of the particle size, and zeta potential distribution indi-
cated that the spherical NPs as effective nano drug deliv-
ery systems were expected to be relatively stable in
physiologic media for intravenous delivery.
In vitro drug release behavior
The release behavior of the NPs is an important aspect
because this information is directly related to the design
of nano drug delivery system. Generally, the release ofFigure 5 In vitro release profiles of PTX-MPEG-PLA NPs versus PTX-PL
phase of burst release. The purple arrows showed their burst start and enddrug from polymeric NPs will depend upon the diffusion
rate of the drug from the NPs, NP stability, and the bio-
degradation rate of the copolymer. If the NPs are stable
and the biodegradation rate of the copolymer is slow,
the release rate will be most likely influenced by the fol-
lowing factors: the strength of the interactions between
the drug and the core block, the physical state of the core,
the drug-loaded content, the molecular volume of the
drug, the length of the core block, and the localization of
the drug within the NPs.
As shown in Figure 5, PTX-PLA NPs and PTX-MPEG-
PLA NPs both presented sustained drug release profiles
with about 42.3% and 78.1% of the total PTX released
from NPs. The accelerated release may be explained by
three factors. First, the particle size of the PTX-MPEG-
PLA NPs was much smaller than that of the PTX-PLA
NPs, reducing the total releasing time of the drug from
the NPs. Second, the presence of hydrophilic PEG in the
polymer NPs reduced the hydrophobic interaction be-
tween the drug and matrix. Third, the outer PEG mol-
ecule could induce easier penetration of the water and
facilitated the bulk erosion of the polymer matrix. All the
factors, singly or in combination, could promote the re-
lease of PTX from the PTX-MPEG-PLA NPs.
Of note, in the case of PTX-PLA NPs, a drug release
behavior can be divided into two phases: the first one
considered as a relatively fast release phase at the initial
stage, commonly ascribing to the easy release of free PTX
absorbed on the surface of the NPs by simple diffusion,
and subsequently, the second one considered as a con-
stantly prolonged release phase, which is most likelyA NPs in PBS (1/15 M, pH 7.4). The blue line represents the second
point.
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by a diffusion-controlled mechanism. In the case of PTX-
MPEG-PLA NPs, these release behaviors were different;
the first abrupt release of PTX was minor from 0 to 12 h,
which may have resulted from the steric effect of long PEG
chain, which led to the low risk and reduced toxicity. Sub-
sequently after the long sustained release by a diffusion-
controlled mechanism, the second abrupt release of PTX
from the NPs presented at 80 h, which was likely attributed
to the deprotection of PEG as a result of the hydrolysis of
MPEG-PLA, suggesting that the presence of hydrophilic
PEG on the surface of NPs could eventually favor PTX to
penetrate from the NPs.
In vitro cellular uptake
First, as may be seen from Figure 6, a predominant and
strong accumulation of red signals in the cell cytoplasm
was observed. The phenomenon demonstrated that rhoda-
mine B-labeled PTX-PLA NPs and PTX-MPEG-PLA NPs
could be uptaken into the cells. Thus, the NPs entering
into cells could play the role of a drug storehouse, effec-
tively exerting their pharmacological and biological effects.
Furthermore, it is very interesting to note that the fluores-
cent signals of PTX-PLA NPs were much stronger than
those of PTX-MPEG-PLA NPs. The results were specu-
lated to be associated with these important reasons. Firstly,
a great deal of hydrophilic PEG on the surface of MPEG-
PLA NPs could prevent the PLA core from transporting
across the lipid-rich cell membranes and entering the in-
ternal environment of the cells. Secondly, the lipophilicity
of PLA facilitated the delivery of NPs to the interior of the
cells across the phospholipid bilayer of cellular membranes.
Lastly, there is also some contribution of the large particle
size of PTX-PLA NPs, which was in favor of entrappingFigure 6 CLSM images of cells incubated with PTX-loaded NPs
which were labeled by rhodamine B. For each panel, the images
from left to right showed rhodamine B fluorescence in cells (red),
cell nuclei stained by Hochest 33258 (blue), and overlays of the two
images. (A) PTX-PLA NPs, (B) PTX-MPEG-PLA NPs.more rhodamine B. In consequence, powerful red fluores-
cent signals could be seen in the cell. However, there is an-
other possibility that the large particle size of PTX-PLA
NPs resulted in the aggregation of NPs. Then the aggre-
gates became too large to enter the cell, so the strong red
dot signals were from the PTX-PLA NPs absorbed on the
cell surface. In this case, both PTX-PLA NPs and PTX-
MPEG-PLA NPs had similar cellular uptake.
In vitro cell viability assays
As shown in Figure 7, the survival rate of A549 cells was
basically suppressed in a drug dose-dependent manner
by free PTX, PTX-PLA NPs, and PTX-MPEG-PLA NPs.
Interestingly, the lowest concentration group (loaded
with an equivalent amount of PTX) of the PTX-MPEG-
PLA NPs observably presented lower cell viability than
that of free PTX with the concentration of 2.5 μg/mL
(P < 0.05), indicating that the PTX-MPEG-PLA NPs
presented a more effective bioavailability compared with
the free PTX solution. On the contrary, the other groups
with the concentration of 10, 20, and 40 μg/mL of PTX-
MPEG-PLA NPs presented a significantly low level of
inhibition effect compared to free PTX. This different
phenomenon could be explained by the cell penetration
rate of drug depending on NP advantage and drug
concentration differences between the internal and ex-
ternal environment of the cell membrane. It should be
emphasized that, in the case of the lowest concentration
(2.5 μg/mL) of PTX, the NP advantage played a rather
important role in the cell penetration rate of drug; their
particle size can easily and virtually increase the cellular
uptake of drug and the accumulation in the cell through
endocytosis mechanism. However, in the case of other
high concentrations of PTX (10, 20, and 40 μg/mL), the
drug concentration differences played a main role. Most
importantly, it was speculated that there were a moreFigure 7 In vitro cell viability assays for growth inhibition effect
after 48 h (n = 6).
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time to reach release equilibrium for the PTX-MPEG-
PLA NPs compared to free PTX. Therefore, the drug
was released incompletely from the NPs in 48 h. Thus,
PTX-MPEG-PLA NPs are promising in the expansion of
dosing range of chemotherapeutic drugs and rendering
patients safe cancer therapy. Additionally, it was inter-
esting to note that the cell viability in PTX-MPEG-PLA
NPs was higher than that in PTX-PLA NPs at a series of
increasing concentrations (2.5, 10, 20, and 40 μg/mL).
This result can most likely be attributed to the drug re-
lease rate of the PTX-MPEG-PLA NPs being higher than
that of the PTX-PLA NPs.
Conclusions
In our previous study, a simple but successful method was
developed to obtain PTX-MPEG-PLA NPs with appropri-
ate formulation characteristics including small particle size,
narrow particle size distribution, high zeta potential, satis-
factory drug encapsulation efficiency, and appreciable drug-
loaded content. The PTX-MPEG-PLA NPs presented a
faster drug release rate but minor burst release as well as
a higher cell cytotoxicity compared to the PTX-loaded PLA
NPs. A further study on the in vivo pharmacokinetics
and antitumor effects of PTX-MPEG-PLA NPs is currently
in progress.
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